title: Relationship between clinical data and gene expression in the HER2/ErbB2-dependent signaling pathway in patients with acute heart failure.
abstract: Anticancer treatment with the human epidermal growth factor receptor (HER) 2 inhibitors can lead to significant myocardial dysfunction. The primary aim of the study was to estimate the possible association between gene expression in the ErbB signaling pathway and selected clinical event data in patients with acute heart failure. Twenty-four patients (19 males), aged 68.6 ± 12.3 years, were diagnosed and treated due to acute heart failure. The globaltest method was used for the correlation between blood nuclear cells' gene expression in the ErbB pathway (KEGG pathway id 04012) and important clinical data. Decreased expression of ErbB2/HER2 was found to be associated with the release of troponin and the need for inotropic support, whereas decreased neuregulin 1 (NRG1) expression was found to be associated with a decrease of ejection fraction below 40 % (globaltest p-value < 0.05). In summary, the ErbB signaling pathway and, especially, HER2/ErbB2 receptor expression are significantly associated with some of the recognized, clinically significant parameters of patients with acute heart failure. Evaluation of the molecular function of the HER2 receptor may be essential for the prognosis and targeted therapy of heart diseases.
authors: First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland, s.szmit@gmail.com.
authors: Sebastian
authors: S
authors: Szmit
authors: Michał
authors: M
authors: Jank
authors: Henryk
authors: H
authors: Maciejewski
authors: Paweł
authors: P
authors: Balsam
authors: Magdalena
authors: M
authors: Łój
authors: Krzysztof J
authors: KJ
authors: Filipiak
authors: Tomasz
authors: T
authors: Motyl
authors: Grzegorz
authors: G
authors: Opolski
mesh_terms: D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology; D002316:Cardiotonic Agents / Q000494:pharmacology; D005260:Female; D015870:Gene Expression; D006333:Heart Failure / Q000175:diagnosis* / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020890:Neuregulin-1 / Q000235:genetics / Q000378:metabolism; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D015203:Reproducibility of Results; D015398:Signal Transduction; D059467:Transcriptome; D014336:Troponin / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D002316:Cardiotonic Agents; D020890:Neuregulin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; D014336:Troponin; C094131:NRG1 protein, human; C508053:ERBB2 protein, human
references: J Clin Oncol. 2010 Jul 20;28(21):3416-21
references: 20530275
references: Mayo Clin Proc. 2008 Jun;83(6):679-86
references: 18533085
references: Nat Med. 2002 May;8(5):459-65
references: 11984589
references: Eur J Heart Fail. 2011 Jan;13(1):83-92
references: 20810473
references: Int Heart J. 2010 Mar;51(2):141-5
references: 20379051
references: J Clin Oncol. 2002 Mar 1;20(5):1156-7
references: 11870153
references: Clin Breast Cancer. 2008 Mar;8 Suppl 3:S114-20
references: 18777950
references: Circulation. 2009 Jul 28;120(4):310-7
references: 19597049
references: J Clin Oncol. 2010 Jul 20;28(21):3422-8
references: 20530280
references: Bioinformatics. 2004 Jan 1;20(1):93-9
references: 14693814
references: J Clin Oncol. 2010 Sep 1;28(25):3910-6
references: 20679614
references: Ann Oncol. 2012 Oct;23 Suppl 7:vii155-66
references: 22997448
references: Oncologist. 2006;11 Suppl 1:4-12
references: 16971734
references: Breast. 2013 Feb;22(1):1-12
references: 23084121
references: J Clin Oncol. 2005 Nov 1;23(31):7811-9
references: 16258083
references: J Clin Oncol. 2007 Sep 1;25(25):3859-65
references: 17646669
references: Cancer Res. 2002 Jun 1;62(11):3151-8
references: 12036928
references: N Engl J Med. 2006 Feb 23;354(8):789-90
references: 16495390
references: Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H660-6
references: 15833803
references: J Clin Oncol. 2005 Nov 1;23(31):7820-6
references: 16258084
references: Recent Prog Horm Res. 2004;59:1-12
references: 14749494
references: Ann Oncol. 2012 Mar;23(3):791-800
references: 21665955
references: J Clin Oncol. 2002 Mar 1;20(5):1215-21
references: 11870163
references: Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8880-5
references: 12072561
references: Curr Pharm Des. 2011;17(18):1808-17
references: 21631420
references: Circulation. 2002 Apr 2;105(13):1551-4
references: 11927521
references: Kardiol Pol. 2011;69(5):520-30
references: 21594854
references: Future Oncol. 2013 Feb;9(2):179-81
references: 23414468
references: Circ Res. 2010 Jan 8;106(1):21-34
references: 20056943
references: J Clin Oncol. 2008 Mar 10;26(8):1231-8
references: 18250349